Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies

被引：3

作者：

deJong, MD

Boucher, CAB

Cooper, DA

Galasso, GJ

Gazzard, B

Lange, JMA

Montaner, JS

Richman, DD

Thomas, HC

机构：

[1] UNIV UTRECHT, EIJKMAN WINKLER INST, DEPT VIROL, UTRECHT, NETHERLANDS

[2] UNIV NEW S WALES, HIV MED UNIT, ST VINCENTS HOSP, SYDNEY, NSW, AUSTRALIA

[3] NATL FDN BIOMED RES, BETHESDA, MD USA

[4] CHELSEA & WESTMINSTER HOSP, DEPT HIV GUM, LONDON, ENGLAND

[5] UNIV AMSTERDAM, ACAD MED CTR, NATL AIDS THERAPY EVALUAT CTR, DEPT INFECT DIS TROP MED & AIDS, NL-1105 AZ AMSTERDAM, NETHERLANDS

[6] UNIV BRITISH COLUMBIA, ST PAULS HOSP, BRITISH COLUMBIA CTR EXCELLENCE HIV AIDS, VANCOUVER, BC V5Z 1M9, CANADA

[7] UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA

[8] UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA

[9] UNIV CALIF SAN DIEGO, SAN DIEGO VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA

[10] UNIV LONDON, ST MARYS HOSP, DEPT MED, LONDON, ENGLAND

来源：

ANTIVIRAL RESEARCH | 1997年 / 35卷 / 02期

关键词：

D O I：

10.1016/S0166-3542(97)00020-X

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：65 / 82

页数：18

共 130 条

[1] HERPES-LIKE SEQUENCES IN HIV-INFECTED AND UNINFECTED KAPOSIS-SARCOMA PATIENTS [J].

AMBROZIAK, JA ;

BLACKBOURN, DJ ;

HERNDIER, BG ;

GLOGAU, RG ;

GULLETT, JH ;

MCDONALD, AR ;

LENNETTE, ET ;

LEVY, JA .

SCIENCE, 1995, 268 (5210) :582-583

[2]

[Anonymous], 1996, Arch Ophthalmol, V114, P23

[3] FOSCARNET FOR TREATMENT OF CYTOMEGALOVIRUS INFECTIONS IN BONE-MARROW TRANSPLANT RECIPIENTS [J].

ASCHAN, J ;

RINGDEN, O ;

LJUNGMAN, P ;

LONNQVIST, B ;

OHLMAN, S .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (02) :143-150

[4] ACTIVITY OF PENCICLOVIR AGAINST EPSTEIN-BARR-VIRUS [J].

BACON, TH ;

BOYD, MR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1599-1602

[5] Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS [J].

Baldanti, F ;

Underwood, MR ;

Stanat, SC ;

Biron, KK ;

Chou, SW ;

Sarasini, A ;

Silini, E ;

Gerna, G .

JOURNAL OF VIROLOGY, 1996, 70 (03) :1390-1395

[6] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

[7] EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS [J].

BENHAMOU, Y ;

DOHIN, E ;

LUNELFABIANI, F ;

POYNARD, T ;

HURAUX, JM ;

KATLAMA, C ;

OPOLON, P ;

GENTILINI, M .

LANCET, 1995, 345 (8946) :396-397

[8] VALACICLOVIR COMPARED WITH ACYCLOVIR FOR IMPROVED THERAPY FOR HERPES-ZOSTER IN IMMUNOCOMPETENT ADULTS [J].

BEUTNER, KR ;

FRIEDMAN, DJ ;

FORSZPANIAK, C ;

ANDERSEN, PL ;

WOOD, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1546-1553

[9] Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS [J].

Bigoni, B ;

Dolcetti, R ;

deLellis, L ;

Carbone, A ;

Boiocchi, M ;

Cassai, E ;

DiLuca, D .

JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03) :542-549

[10]

BIRON F, 1995, J ACQ IMMUN DEF SYND, V10, P36

← 1 2 3 4 5 6 7 8 9 10 →